Torrent Pharma launches 3 new specialty divisions

Ahmedabad-based pharma major, Torrent Pharma has launched 3 new specialty divisions - Omega, Sensa and Alfa. The new divisions will exclusively cater to the fast growing niche therapeutic areas of Cardio-Diabeta, Central Nervous System (CNS) and Gastro segments respectively.Omega, the new cardio-diabeta (C&D) division, will exclusively focus on cardio-metabolic diseases, with special focus on diabetes and nephrology.

Torrent, with sales of Rs 180 crore, currently has a 4.8% share in the Rs 3750 crore C&D market. The new CNS division, Sensa, will focus exclusively on ailments afflicting the geriatric population. This includes Parkinsons, Alzheimers and depression. The CNS market in India is estimated to be around Rs 1200 crore of which Torrent has a 5.5% share. It has been growing at almost 2.5 times faster than the industry, clocking 50% growth as per ORG MAT, July 2006.With 60 new field personnel, Sensa will reach out to more specialists in this niche population segment.
The third new division, Alfa is in the mass products segment and will focus on Gastro, Ortho, and Anti-Infectives segments. The gastro-intestinal market is worth around Rs 3000 crore and is growing at 19%. Alfa will join the existing divisions, Prima and Vista, in this category and is expected to substantially push segment revenues from the current Rs 262 crore (ORG July MAT 2006). The company plans to deploy around 200 new field personnel in this new division to drive growth.

"Divisionalisation will help us launch molecules with greater regularity. This will ensure better doctor coverage, more prescriptions and therefore, higher sales revenues," Ruchir Modi, head (strategic marketing) of Torrent, said.